The DART trial, testing combination immunotherapy in a wide range of rare tumors, has completed enrollment to most of its 52 cohorts of patients. But two rare lung cancer cohorts still need a few more patients:

- Sarcomatoid carcinoma of the lung
- Bronchoalveolar carcinoma

DART (S1609) is open at almost 1,000 sites nationwide – your site probably already has it open. If you have patients with these rare tumors, please consider enrolling them to DART.

S1800D Lung-MAP Non-match Sub-study: Required Training in CTSU’s CLASS

Lung-MAP’s newest non-match sub-study opened in February: the S1800D trial of N-803 + pembrolizumab vs standard of care. This is the first sub-study in which required training is provided through the new CTSU Compliance, Learning, and SOP Solutions (CLASS) learning management system. You have questions about CLASS? We have answers.

Q: How do I complete the protocol-specific required training?
A: To enroll patients to S1800D, at least one staff member at your site must complete the S1800D Training Webinar in CTSU’s CLASS system (unless you completed the online training and verification form on the SWOG website before February 15th).

- Log into CLASS at https://ctsu.org/public/CLASS.aspx
- Click the Catalog button
- Click the course SWOG: S1800D Site

Initiation Training (look for the SWOG logo)
- Click the Enroll button below this course name.

The course includes a 20-minute video presentation and slide set.

Q: How can I access proof that I’ve completed training?
A: You could click on Transcript in CLASS’s drop-down menu (at upper right), but if your site can register patients to S1800D, that’s proof someone there has completed the required training. Moreover, once one of your staff does complete the CLASS training, site certification to enroll patients to S1800D is automatic (assuming you've satisfied all other regulatory requirements).

Two DART Trial Cohorts Looking for Patients with Rare Lung Cancers

The DART trial, testing combination immunotherapy in a wide range of rare tumors, has completed enrollment to most of its 52 cohorts of patients. But two rare lung cancer cohorts still need a few more patients:

- Sarcomatoid carcinoma of the lung
- Bronchoalveolar carcinoma

DART (S1609) is open at almost 1,000 sites nationwide – your site probably already has it open. If you have patients with these rare tumors, please consider enrolling them to DART.

Lung-MAP Patient Handout Available on CTSU.org

An informational handout for Lung-MAP patients that has been available on lung-map.org is now also on CTSU.org. This flyer has been CIRB-approved since 2018 and does not contain new or updated information – it’s just now more readily accessible.

SNEAK PEEK: Lung-MAP's next sub-study, S1900F, is approaching the launch pad. Stay tuned!
The Lung-MAP Site Coordinators Committee (SCC) is here for you — with a mission “to represent study site staff at the nursing, CRA, data management, and regulatory levels by providing feedback to and from the study leadership to enhance accrual and improve study management.”

Five new members were voted into the SCC earlier this year. We introduce two of them here and will introduce the other three in the next issue.

Danielle Bednarz, BS, RN, is the lead Lung-MAP member for the 35 satellite sites associated with the UPMC Hillman Cancer Center in Pittsburgh, which is the study’s highest accruing institution (see the list below). She says she’s fallen in love with research during the three and one-half years she has worked with Lung-MAP — facilitating patient transfers, screening and enrolling patients, providing patient care, and educating staff about the study. Lung-MAP is feeling the love!

Kenya Mitchell, AAB, BA, CCRP, is a regulatory coordinator with St. Luke’s Hospital of Kansas City, deep in the U.S. heartland. She brings to her role with the Lung-MAP team more than 20 years of research administration experience, which includes stints as a senior clinical trials assistant and a liver transplant research coordinator. An international traveler with degrees in business administration and organizational leadership, Kenya finds satisfaction working in research “because we make life better for the future of those who are sick.” Well said!

You’re Invited! Lung-MAP Update at SWOG Group Meeting

All sites are invited to attend the Lung-MAP update session at the SWOG spring group meeting via Zoom (or in person in Seattle!), Friday, April 8, 2:30-4 pm PT, at bit.ly/36yhyzf. A great way to stay up-to-date on Lung-MAP!

As of March 23, 2022, the new LUNGMAP protocol has logged:

- 2,374 screening registrations
- 1,279 sub-study assignments
- 330 sub-study registrations

TOP-ACCRUING SITES AS OF 3/23/2022

1. UPMC Hillman Cancer Center Pittsburgh, PA 142
2. Wilmot Cancer Institute Rochester, NY 45
3. UNM Comprehensive Cancer Center Albuquerque, NM 44
4. Mercy Medical Center Canton, OH 40
5. Missouri Baptist Medical Center St. Louis, MO 33
6. Edwards Comprehensive Cancer Center Huntington, WV 29
6. VA Connecticut Healthcare System – West Haven West Haven, CT 29
7. Roswell Park Comprehensive Cancer Center Buffalo, NY 27
8. Baystate Medical Center Springfield, MA 26
9. Markey Cancer Center Lexington, KY 25
9. Stephenson Cancer Center Oklahoma City, OK 25
10. Good Samaritan Hospital Cincinnati, OH 24
10. Eastern Maine Medical Center Cancer Care Brewer, ME 24

CONTACT US

General Medical Questions LUNGMAP@swog.org
Protocol & Regulatory Questions lgildner@swog.org or jbeeler@swog.org
Eligibility & Data Submission Questions LUNGMAPQuestion@crab.org

Central Monitoring Questions centralmonitorquestion@crab.org
Quality Assurance Auditing Questions qamail@swog.org

Funding Questions funding@swog.org
S1900E Study Chairs S1900EMedicalQuery@swog.org
S1800D Study Chairs S1800DMedicalQuery@swog.org